Trial Profile
Sitagliptin, a DPP-4 inhibitor, increases the number of circulating CD34+CXCR4+cells in patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Mar 2016
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Mar 2016 New trial record